Astellas Pharma (ALPMY) Upgraded to Strong Buy: What Does It Mean for the Stock?
Astellas Pharma (ALPMY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to…
8,532€
-2,36%
Echtzeit-Aktienkurs Astellas Pharma Inc.
Bid:
Ask:
Nachrichten zur Astellas Pharma Inc. Aktie
Astellas Pharma Inc. (ALPMF) Q4 2024 Earnings Call Transcript
…
Astellas Pharma: Raising New, As Yet Unanswered Questions In Stomach Cancer And Moving Their Pipeline Forward
…
Astellas Pharma Inc. (ALPMF) Q3 2024 Earnings Call Transcript
…
Astellas Pharma Inc. 2024 Q3 - Results - Earnings Call Presentation
…
Antibody Drug Conjugates Market Outlook 2025-2035, with Forecasts for Payload Type, Linker Type, Target Antigen and Applications
Dublin, Jan. 15, 2025 (GLOBE NEWSWIRE) -- The "Antibody Drug Conjugates Market Report 2025-2035" has been added to…
Astellas Pharma Inc. (ALPMF) Q2 2024 Earnings Call Transcript
…
Global Prostate Health Market Size To Worth USD 78.03 Billion By 2033 | CAGR Of 9.12%
The Global Prostate Health Market Size was Valued at USD 32.6 Billion in 2023 and the Worldwide Prostate Health Market…
Astellas Pharmas Okamura on Business Outlook
Naoki Okamura, CEO of Astellas Pharma, discusses his business strategy for the company and the outlook for Japans economic growth…
Antiandrogens Market Insights and Projections to 2030: An $8.7 Billion Landscape Dominated by Pfizer, Astellas Pharma, Roche, AstraZeneca, and Abbott Labs
Dublin, May 21, 2024 (GLOBE NEWSWIRE) -- The "Antiandrogens Market Report: Trends, Forecast and Competitive Analysis to 2030"…
Global Liver Disease Therapeutics Market to Grow Rapidly by 2030, Examines DelveInsight | Key Players in the Market - AbbVie, GSK, F.Hoffmann-La Roche, Bristol-Myers Squibb Company, Abbott, Gilead Sciences, Astellas Pharma
The surge in liver disease therapeutics demand stems mainly from a growing population afflicted with liver ailments, elevated alcohol intake,…
Earnings call: Astellas Pharma exceeds revenue forecast, faces profit dip By Investing.com
Earnings call: Astellas Pharma exceeds revenue forecast, faces profit dip…
Astellas Pharma Inc. (ALPMF) Q4 2023 Earnings Call Transcript
…
Vasomotor Symptoms Market is Likely to Increase at a Steady Growth Rate by 2034, Estimated DelveInsight | Key Companies - Estetra, Bayer, Hansoh BioMedical R&D Company, Mitsubishi Tanabe Pharma, Astellas Pharma Inc
The vasomotor symptoms market is expected to experience substantial growth in the upcoming years, driven by the introduction of new…